Latest

Do Sales Reps Hold the Key to Better Pharma Insights?

Whether a brand is preparing to launch a new product, or taking a reinvigorated one back to market, it is widely accepted that those who form the emotional connection with customers are most likely to succeed.

Planning for the Future of Serialization

Compliance with the new traceability requirements necessitates an understanding of how and when to begin implementing changes in an ever-evolving industry.

New & Noteworthy

Hot and Cold: Biotech M&A and Financial Trends

The overall impression from the media is that the biotech industry is doing a great job inventing new drugs and treatments and that strong companies are getting the funding they need. But it's not that clear cut, writes Peter Young.

Regulatory Dark Horse? EU Directive on Cross-Border Patients’ Rights

Reflector looks at the revitalized European Union directive on patients’ rights in cross-border healthcare.

Refuting R&D Tax Credit Myths

Why executives should make the US R&D tax credit part of their planning discussions.

What Does the UK's "New" Government Mean for the Industry?

Following the Conservatives surprise majority win in the UK election, Leela Barham asks what does it mean for pharma?

From the Editor

From Care to Cure

This year's Pharm Exec Brand of the Year is a huge game-changers, but the big-picture impact will come down to pricing, distribution, and the broader goal of making sure that those patients who need the cure, get the cure, writes William Looney.

The New Health: Navigating with Nash

Learnings gleaned from our annual EAB meeting, hosted this year by Dr. David Nash, Dean of the Thomas Jefferson University School of Population Health.

Is There Gold in the DNA Selfie?

Pharma jumps on board personal genomics train—at least for test drive—but will journey ultimately help transform treatment or stall out as just another fad?

Europe

NICE Proposes Office of Market Access

NICE's proposed Innovation Office emerges with a new name. Leela Barham reports.

Regulatory Dark Horse? EU Directive on Cross-Border Patients’ Rights

Reflector looks at the revitalized European Union directive on patients’ rights in cross-border healthcare.

New European Guidelines Tackle Controversial HTA Components

EUnetHTA has developed guidelines to help “set a general framework for EUnetHTA on how to conduct economic evaluations”, arguably HTA's most controversial element. Leela Barham reports.

Global

Regulatory Dark Horse? EU Directive on Cross-Border Patients’ Rights

Reflector looks at the revitalized European Union directive on patients’ rights in cross-border healthcare.

Sunshine Over Europe: Event Sheds Light on Disclosure

Sunshine was a strong feature of this week's CBI’s Global Transparency Reporting Congress in London, in more ways than one.

The Goods and Services Tax: A Bane or a Boon for Indian Pharma?

Dr. Anuj Gupta explains the potential implications of the GST— or the goods and services tax — on Indian pharma.

PEspeaks

The Patients 2 Consortium: Accelerating Patient Enrollment in Clinical Trials

Emerging technology partnerships in the biopharma space may be provide hope in accelerating patient enrollment, writes Michael Christel.

Priority Review Voucher Priced at $245m

A hot commodity, the FDA’s Rare Pediatric Disease Priority Review Voucher program once again proved its worth, with today’s $245m transaction.

Generic Opioids Raise Tricky Policy Issues

Widespread use and abuse of opioid painkillers is prompting efforts to develop new drugs and formulations that resist abuse while providing relief to legitimate patients, writes Jill Wechsler.

Speeding Up Clinical Trials: What Works and What Doesn’t

Increasing the speed and efficiency of clinical trials is an agreed-upon priority. What is less apparent, however, is which approaches have worked which haven't in recent years. Michael Christel reports.

Regulatory

Generic Opioids Raise Tricky Policy Issues

Widespread use and abuse of opioid painkillers is prompting efforts to develop new drugs and formulations that resist abuse while providing relief to legitimate patients, writes Jill Wechsler.

“Cures” Debate Far From Over

The House Energy & Commerce (E&C) Committee unanimously approved the 21st Century Cures legislation last week, but the debate is slated to continue for several months, if not longer. Jill Wechsler reports.

Manufacturers Continue to Fight Over Biosimilar Naming

After hearing “strong views” on the issue, FDA is expected to release biosimilar-naming guidance later this year.

Sales & Marketing

Do Sales Reps Hold the Key to Better Pharma Insights?

Whether a brand is preparing to launch a new product, or taking a reinvigorated one back to market, it is widely accepted that those who form the emotional connection with customers are most likely to succeed.

"There's a Cure for That..."

Cures and therapies with curative intent are here in hepatitis C and are imminent in other serious diseases. So what does this mean for pharma stakeholders, from suppliers to patients, asks Mike Rutstein.

Opposites Attract: Pairing R&D and Commercial Teams

Meike Wenzel and Clifford Hall examine a new concept for early commercialization planning to facilitate good cross-functional working practice.

R&D

Refuting R&D Tax Credit Myths

Why executives should make the US R&D tax credit part of their planning discussions.

Pharmacies — A New Patient Education Opportunity

Kenneth Getz of the Tufts Center for the Study of Drug Development looks at leveraging pharmacists as a channel to raise clinical research literacy among patient communities.

Strategy

Capturing the Cloud: A Conversation with Veeva Systems Matt Wallach

Pharm Exec talks to Matt Wallach, President of upstart start-up, Veeva Systems

Opposites Attract: Pairing R&D and Commercial Teams

Meike Wenzel and Clifford Hall examine a new concept for early commercialization planning to facilitate good cross-functional working practice.

Is Procurement Living Up to the Challenge?

Mike Straw offers four key changes to address the "lack of love" for pharmaceutical procurement functions.